Merck Serono announced that based on its recent analysis of the human growth hormones (HGH) market, Frost & Sullivan recognises Merck Serono with the 2013 Europe Product Differentiation Excellence Award. “Merck Serono is lauded for its cutting-edge drug delivery devices - easypod® and cool.click®2 – more

The need to improve the efficiency and quality of X-ray examinations will drive healthcare facilities across Europe to install computed radiography (CR) and digital radiography (DR) systems. The emergence of retrofit systems based on flat panel technology has popularised DR systems, and will sustain more

The European market for interventional radiology and cardiology is heading towards maturity, especially in Western Europe. Although the economic slowdown and fewer orders had a negative impact on revenues in 2012, it is expected that expanding applications of interventional systems and the popularis more

The limited efficacy and negative side-effects associated with current therapeutics for Hepatitis B and C are highlighting the urgent need for new, improved alternatives. Combination therapies offering better clinical outcomes are coming to the fore and look set to transform the European market for more

Image-guided and robot-assisted surgeries have made successful inroads into the western European market. The significant cost and clinical benefits offered by such advanced surgical systems has been key to boosting their adoption rates. New analysis from Frost & Sullivan, Image-guided and Robot-assi more

Remote patient monitoring (RPM) technologies help patients retain their independence and avert further health complications. These technologies can also be a vital tool for governments to curb spiralling healthcare expenditures. New analysis from Frost & Sullivan, European Market for Remote Patient more

The anticipated launch of drugs currently in the pipeline, together with the introduction of oral combination pills, are set to have a profound impact on the European HIV drugs market. New analysis from Frost & Sullivan, Analysis of the European HIV Drugs Market, finds that the market earned $5.58 b more

In recent years, the prevalence of hepatitis C has increased among high risk sub-group populations, including immigrants from areas where the disease is endemic, injecting drug users (IDUs) and patients co-infected with HIV. “Overall, the incidence of hepatitis C among IDUs in Europe is estimated to more

The stable growth of the European human growth hormone (hGH) market is attributed primarily to a decrease in the prices and an increase in the overall volumes of hGH drugs used. No new indications for hGH therapy are likely to be approved by the European Medicines Agency (EMEA) over the next 3 to 5 more

Over 32% of HIV+ people in Europe remain undiagnosed. This large untapped pool and the development of novel nucleic acid test (NAT) and non-NAT technology based platforms offers growth potential for HIV diagnostics manufacturers. New analysis from Frost & Sullivan, Analysis of European HIV Diagnosti more